HRP20110232T1 - Antagonisti muskarinskog acetilkolinskog receptora - Google Patents
Antagonisti muskarinskog acetilkolinskog receptora Download PDFInfo
- Publication number
- HRP20110232T1 HRP20110232T1 HR20110232T HRP20110232T HRP20110232T1 HR P20110232 T1 HRP20110232 T1 HR P20110232T1 HR 20110232 T HR20110232 T HR 20110232T HR P20110232 T HRP20110232 T HR P20110232T HR P20110232 T1 HRP20110232 T1 HR P20110232T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- compound
- intended
- endo
- pharmaceutical preparation
- Prior art date
Links
- 230000003551 muscarinic effect Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 150000001450 anions Chemical class 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 229940112141 dry powder inhaler Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Spoj sa strukturom I ili II, kao što je prikazana niženaznačen time što: prikazani H atom je u položaju exo; R1- predstavlja anion pridružen pozitivnom naboju na N atomu; svaki od R2 i R3 predstavlja fenil; iR4 predstavlja -CN. Patent sadrži još 16 patentnih zahtjeva.
Claims (17)
1. Spoj sa strukturom I ili II, kao što je prikazana niže
[image]
naznačen time što:
prikazani H atom je u položaju exo;
R1– predstavlja anion pridružen pozitivnom naboju na N atomu;
svaki od R2 i R3 predstavlja fenil; i
R4 predstavlja -CN.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu I, niže:
[image]
gdje R1–, R2, R3 i R4 su definirani kao u patentnom zahtjevu 1.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu II:
[image]
gdje R2, R3 i R4 su definirani kao u patentnom zahtjevu 1.
4. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što R1– se bira između bromida, jodida, sulfata, benzensulfonata i toluensulfonata.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-(endo)-8-metil-8-azabiciklo[3.2.1]okt-3-il)-2,2-difenilpropionitril.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (endo)-3-(2-cijano-2,2-difeniletil)-8,8-dimetil-8-azoniabiciklo[3.2.1]oktan-jodid.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (endo)-3-(2-cijano-2,2-difeniletil)-8,8-dimetil-8-azoniabiciklo[3.2.1]oktan-bromid.
8. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i farmaceutski prihvatljivu podlogu.
9. Farmaceutski pripravak, naznačen time što sadrži (endo)-3-(2-cijano-2,2-difeniletil)-8,8-dimetil-8-azoniabiciklo[3.2.1]oktan-jodid.
10. Farmaceutski pripravak, naznačen time što sadrži (endo)-3-(2-cijano-2,2-difeniletil)-8,8-dimetil-8-azoniabiciklo[3.2.1]oktan-bromid.
11. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 8 do 10, naznačen time što je namijenjen primjeni inhalacijom kroz usta ili nos.
12. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 8 do 11, naznačen time što je namijenjen primjeni putem razdavača medikamenta, kojeg se bira između inhalatora sa suhim prahom u spremniku, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
13. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje bolesti posredovane muskarinskim acetilkolinskim receptorom, gdje se acetilkolin veže na navedeni receptor.
14. Upotreba u skladu s patentnim zahtjevom 13, naznačena time što se bolest bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična opstrukcija dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.
15. Upotreba u skladu s patentnim zahtjevom 13 ili patentnim zahtjevom 14, naznačena time što je navedeni spoj namijenjen primjeni inhalacijom kroz usta ili nos.
16. Upotreba u skladu s bilo kojim od patentnih zahtjeva 13 do 15, naznačena time što je navedeni spoj namijenjen primjeni putem razdavača medikamenta, kojeg se bira između inhalatora sa suhim prahom u spremniku, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi u postupku liječenja bolesti koju se bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična opstrukcija dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51100903P | 2003-10-14 | 2003-10-14 | |
| PCT/US2004/033638 WO2005037280A1 (en) | 2003-10-14 | 2004-10-12 | Muscarinic acetycholine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110232T1 true HRP20110232T1 (hr) | 2011-05-31 |
Family
ID=34465175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110232T HRP20110232T1 (hr) | 2003-10-14 | 2011-03-31 | Antagonisti muskarinskog acetilkolinskog receptora |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7276521B2 (hr) |
| EP (1) | EP1677795B1 (hr) |
| JP (4) | JP2007508390A (hr) |
| KR (3) | KR20060106821A (hr) |
| CN (3) | CN101230061A (hr) |
| AP (3) | AP2007004239A0 (hr) |
| AR (1) | AR046103A1 (hr) |
| AT (1) | ATE494285T1 (hr) |
| AU (1) | AU2004281724B2 (hr) |
| BR (1) | BRPI0415361A (hr) |
| CA (1) | CA2542657C (hr) |
| CY (1) | CY1111364T1 (hr) |
| DE (1) | DE602004030930D1 (hr) |
| DK (1) | DK1677795T3 (hr) |
| EA (3) | EA013689B1 (hr) |
| EC (1) | ECSP066468A (hr) |
| ES (1) | ES2358673T3 (hr) |
| HR (1) | HRP20110232T1 (hr) |
| IL (2) | IL174843A0 (hr) |
| IS (1) | IS2918B (hr) |
| MA (1) | MA28110A1 (hr) |
| MX (1) | MXPA06004244A (hr) |
| MY (1) | MY143366A (hr) |
| NO (1) | NO20062042L (hr) |
| NZ (2) | NZ546312A (hr) |
| OA (1) | OA13316A (hr) |
| PE (1) | PE20050963A1 (hr) |
| PL (1) | PL1677795T3 (hr) |
| PT (1) | PT1677795E (hr) |
| SG (1) | SG147436A1 (hr) |
| SI (1) | SI1677795T1 (hr) |
| TW (3) | TW200811171A (hr) |
| UA (2) | UA89734C2 (hr) |
| WO (1) | WO2005037280A1 (hr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200519108A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| TW200811171A (en) | 2003-10-14 | 2008-03-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| OA13270A (en) * | 2003-10-17 | 2007-01-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists. |
| TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2005087236A1 (en) * | 2004-03-11 | 2005-09-22 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| WO2005095407A1 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| WO2005094251A2 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3muscarinic acetylcholine receptor antagonists |
| TWI363759B (en) | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2005112644A2 (en) * | 2004-05-13 | 2005-12-01 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| JP2008520579A (ja) * | 2004-11-15 | 2008-06-19 | グラクソ グループ リミテッド | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| WO2007016639A2 (en) * | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| US7767691B2 (en) * | 2005-08-18 | 2010-08-03 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system |
| BRPI0710240A2 (pt) | 2006-04-20 | 2011-08-09 | Glaxo Group Ltd | composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
| US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| JP2010539182A (ja) * | 2007-09-12 | 2010-12-16 | グラクソ グループ リミテッド | 治療剤の新規組み合わせ |
| AR070563A1 (es) | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias. |
| UY31637A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
| UY31635A1 (es) | 2008-02-06 | 2009-08-31 | Farmacóforos duales-antagonistas muscarínicos de pde4 | |
| JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
| EP3578169B1 (en) | 2009-02-26 | 2024-06-26 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| JO3025B1 (ar) | 2009-04-30 | 2016-09-05 | Glaxo Group Ltd | الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3 |
| GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
| JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| DK2614058T3 (en) | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| KR20140147891A (ko) | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 응집체 입자 |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
| CN105611929A (zh) | 2013-10-17 | 2016-05-25 | 葛兰素史克知识产权开发有限公司 | 用于治疗呼吸系统疾病的pi3k抑制剂 |
| EP3057587A1 (en) | 2013-10-17 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| CN107072976A (zh) | 2014-05-12 | 2017-08-18 | 葛兰素史克知识产权第二有限公司 | 用于治疗传染性疾病的包含Danirixin的药物组合物 |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2800482A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
| US2800478A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
| US2800481A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
| AT298118B (de) | 1967-06-08 | 1972-04-25 | Siemens Ag | Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens |
| GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
| CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| NO166268C (no) | 1985-07-30 | 1991-07-03 | Glaxo Group Ltd | Innretning for administrering av medikamenter til pasienter. |
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| GB8923590D0 (en) * | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| GB9000304D0 (en) * | 1990-01-06 | 1990-03-07 | Pfizer Ltd | Muscarinic receptor antagonists |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| JP3294961B2 (ja) * | 1993-12-10 | 2002-06-24 | 杏林製薬株式会社 | 新規イミダゾール誘導体及びその製造法 |
| JPH08291141A (ja) * | 1995-04-21 | 1996-11-05 | Kotobuki Seiyaku Kk | ジフェニル酢酸誘導体及びその製造法 |
| JPH0920758A (ja) * | 1995-07-06 | 1997-01-21 | Kyorin Pharmaceut Co Ltd | 新規環状ジアミン誘導体及びその製造法 |
| WO1998024788A1 (en) * | 1996-12-02 | 1998-06-11 | Georgetown University | Tropane derivatives and method for their synthesis |
| US6248752B1 (en) * | 1998-02-27 | 2001-06-19 | Charles Duane Smith | Azabicyclooctane compositions and methods for enhancing chemotherapy |
| US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7361668B2 (en) * | 2001-10-17 | 2008-04-22 | Ucb, S.A. | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| US6696462B2 (en) | 2002-01-31 | 2004-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions |
| DE10211700A1 (de) * | 2002-03-16 | 2003-09-25 | Boehringer Ingelheim Pharma | Neue Difurylglykolsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| AR040779A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion |
| US7232841B2 (en) * | 2003-04-07 | 2007-06-19 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| PE20050711A1 (es) * | 2003-07-17 | 2005-09-10 | Glaxo Group Ltd | Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina |
| PE20050327A1 (es) | 2003-07-17 | 2005-06-08 | Glaxo Group Ltd | Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina |
| TW200519108A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| TW200811171A (en) * | 2003-10-14 | 2008-03-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| ATE435855T1 (de) | 2003-11-21 | 2009-07-15 | Theravance Inc | Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor |
| EP1824483A4 (en) | 2004-10-29 | 2009-11-04 | Glaxo Group Ltd | ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS |
| WO2006055503A2 (en) | 2004-11-15 | 2006-05-26 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| JP2008520579A (ja) | 2004-11-15 | 2008-06-19 | グラクソ グループ リミテッド | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| PE20061162A1 (es) | 2004-12-06 | 2006-10-14 | Smithkline Beecham Corp | Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos |
| PE20060826A1 (es) | 2004-12-06 | 2006-10-08 | Smithkline Beecham Corp | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2006065788A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Novel muscarinic acetylcholine receptor antagonists |
| WO2007018508A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetycholine receptor antagonists |
| WO2007018514A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| EP1937230A4 (en) | 2005-08-02 | 2009-08-26 | Glaxo Group Ltd | M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| WO2007016639A2 (en) | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| US7767691B2 (en) | 2005-08-18 | 2010-08-03 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system |
-
2004
- 2004-10-12 TW TW096137867A patent/TW200811171A/zh unknown
- 2004-10-12 OA OA1200600122A patent/OA13316A/en unknown
- 2004-10-12 BR BRPI0415361-8A patent/BRPI0415361A/pt not_active Application Discontinuation
- 2004-10-12 AR ARP040103693A patent/AR046103A1/es not_active Application Discontinuation
- 2004-10-12 PL PL04794886T patent/PL1677795T3/pl unknown
- 2004-10-12 AP AP2007004239A patent/AP2007004239A0/xx unknown
- 2004-10-12 CN CNA2008100092898A patent/CN101230061A/zh active Pending
- 2004-10-12 AU AU2004281724A patent/AU2004281724B2/en not_active Ceased
- 2004-10-12 EA EA200702619A patent/EA013689B1/ru not_active IP Right Cessation
- 2004-10-12 AP AP2007004238A patent/AP2007004238A0/xx unknown
- 2004-10-12 TW TW096137868A patent/TW200811172A/zh unknown
- 2004-10-12 UA UAA200900439A patent/UA89734C2/ru unknown
- 2004-10-12 SG SG200807641-6A patent/SG147436A1/en unknown
- 2004-10-12 MX MXPA06004244A patent/MXPA06004244A/es active IP Right Grant
- 2004-10-12 KR KR1020067007082A patent/KR20060106821A/ko not_active Application Discontinuation
- 2004-10-12 MY MYPI20044177A patent/MY143366A/en unknown
- 2004-10-12 US US10/575,839 patent/US7276521B2/en not_active Expired - Fee Related
- 2004-10-12 AT AT04794886T patent/ATE494285T1/de active
- 2004-10-12 ES ES04794886T patent/ES2358673T3/es active Active
- 2004-10-12 KR KR1020087016103A patent/KR20080067023A/ko not_active Application Discontinuation
- 2004-10-12 DE DE602004030930T patent/DE602004030930D1/de active Active
- 2004-10-12 CN CNA2008100092900A patent/CN101230062A/zh active Pending
- 2004-10-12 NZ NZ546312A patent/NZ546312A/en unknown
- 2004-10-12 SI SI200431631T patent/SI1677795T1/sl unknown
- 2004-10-12 PT PT04794886T patent/PT1677795E/pt unknown
- 2004-10-12 AP AP2006003566A patent/AP1828A/xx active
- 2004-10-12 UA UAA200604113A patent/UA87473C2/ru unknown
- 2004-10-12 JP JP2006535591A patent/JP2007508390A/ja active Pending
- 2004-10-12 TW TW093130797A patent/TWI409060B/zh not_active IP Right Cessation
- 2004-10-12 CN CNA2004800372668A patent/CN1893948A/zh active Pending
- 2004-10-12 EA EA200702617A patent/EA013435B1/ru not_active IP Right Cessation
- 2004-10-12 NZ NZ556424A patent/NZ556424A/en unknown
- 2004-10-12 PE PE2004000982A patent/PE20050963A1/es not_active Application Discontinuation
- 2004-10-12 DK DK04794886.4T patent/DK1677795T3/da active
- 2004-10-12 CA CA2542657A patent/CA2542657C/en not_active Expired - Fee Related
- 2004-10-12 EA EA200600773A patent/EA009899B1/ru not_active IP Right Cessation
- 2004-10-12 WO PCT/US2004/033638 patent/WO2005037280A1/en active Application Filing
- 2004-10-12 KR KR1020087016101A patent/KR20080065318A/ko not_active Application Discontinuation
- 2004-10-12 EP EP04794886A patent/EP1677795B1/en active Active
-
2006
- 2006-03-31 EC EC2006006468A patent/ECSP066468A/es unknown
- 2006-04-06 IL IL174843A patent/IL174843A0/en unknown
- 2006-04-25 MA MA28964A patent/MA28110A1/fr unknown
- 2006-05-05 IS IS8441A patent/IS2918B/is unknown
- 2006-05-08 NO NO20062042A patent/NO20062042L/no not_active Application Discontinuation
-
2007
- 2007-06-21 US US11/766,318 patent/US7579361B2/en not_active Expired - Fee Related
- 2007-06-21 US US11/766,371 patent/US7576096B2/en not_active Expired - Fee Related
- 2007-08-02 JP JP2007201719A patent/JP2007314567A/ja active Pending
- 2007-08-02 JP JP2007201718A patent/JP4796552B2/ja not_active Expired - Fee Related
- 2007-12-13 IL IL188112A patent/IL188112A/en not_active IP Right Cessation
-
2011
- 2011-03-30 CY CY20111100339T patent/CY1111364T1/el unknown
- 2011-03-31 HR HR20110232T patent/HRP20110232T1/hr unknown
- 2011-05-16 JP JP2011109756A patent/JP5450509B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110232T1 (hr) | Antagonisti muskarinskog acetilkolinskog receptora | |
| HRP20120775T1 (hr) | Antagonisti m3 muskarinskog acetilkolinskog receptora | |
| JP2011162556A5 (hr) | ||
| HRP20120832T1 (hr) | Antagonisti muskarinskih acetilkolinskih receptora | |
| RU2006129289A (ru) | Антагонисты мускариновых ацетилхолиновых рецепторов | |
| Anderson et al. | Inhaled medicines: past, present, and future | |
| ES2248409T3 (es) | Derivados de carbamato de quinuclidina y su uso como antagonistas de m3. | |
| ES2215147T3 (es) | Agentes anticolinergicos utilizables como medicamentos, asi como procedimiento para su preparacion. | |
| US7122558B2 (en) | Quinuclidine derivatives and medicinal compositions containing the same | |
| ES2193098T7 (es) | Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3 | |
| RU2006104854A (ru) | Антагонисты мускариновых ацетилхолиновых рецепторов | |
| JP2009525343A5 (hr) | ||
| NO20050164L (no) | Nye quinuklidin-amid-derivater | |
| ES2203327B1 (es) | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. | |
| CA2496699A1 (en) | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids | |
| WO2008012290A3 (en) | Quinuclidine derivatives as m3 antagonists | |
| AU2012210652B2 (en) | Use of nicotinic acetylcholine receptor alpha 7 activators | |
| NZ593695A (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
| RU2006104851A (ru) | Антагонисты мускариновых рецепторов ацетилхолина | |
| TW200307681A (en) | New pharmaceutical compositions based on anticholinergics and P38 kinase inhibitors | |
| PT88296B (pt) | Processo para a preparacao de esteres e de amidas de acidos carboxilicos ciclicos e de alcoois ciclicos e de aminas | |
| JP2008531558A5 (hr) | ||
| CA2733294A1 (en) | Pharmaceutical combination of a tiotropium salt and ciclesonide | |
| JP2007524698A5 (hr) | ||
| CA2457717A1 (en) | Use of compounds in a dry powder inhaler |